NIH Begins Early Human Clinical Trial Of Temperature-Stable TB Vaccine, Reports Early-Stage Trial Results Of Ebola Treatment

National Institutes of Health: Temperature-stable experimental tuberculosis vaccine enters clinical testing
“Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. … Many vaccines require a temperature-controlled system during transport, which can be costly and logistically challenging. Freeze-dried powder vaccines can be distributed at a cheaper cost to remote, low-resource settings…” (1/23).

National Institutes of Health: Investigational monoclonal antibody to treat Ebola is safe in adults
“The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. … The investigational treatment is currently being offered to Ebola patients in the Democratic Republic of the Congo (DRC) under compassionate use and as part of a Phase 2/3 clinical trial of multiple investigational treatments. … The authors note several advantages for deploying mAb114 in an outbreak setting, including the ease and speed of its administration, and its formulation as a freeze-dried powder that does not require freezer storage…” (1/25).